The most exciting news today is about some research performed at the University of Pennsylvania where researchers took blood from the three leukemia patients and isolated the T cells, a type of immune cell in the blood. T cells recognize invading organisms and kill them, however they do not recognize cancer cells as invading cells, [...]
Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They have not been asked to make any modifications due to efficacy or to safety concerns. This decision is based on [...]
In anticipation of our Monday night teleconference on Provenge (see below for registration procedures) I am very happy to report that Dendreon is now detailing plans to move Provenge to earlier stages in the disease’s progress. At the American Society of Clinical Oncology (ASCO) meeting in Chicago which is winding down today, Dendreon unveiled plans [...]
It was announced today that the first patient in the TERRAIN study received their first dose in the Phase 2 trial of the investigational drug MDV3100 . MDV3100 is a triple-acting oral androgen receptor antagonist that I have writing about as a drug “On The Horizon”. Triple-acting means that it blocks testosterone binding to the [...]
A new Phase 2 clinical trial of tesetaxel in men with castrate resistant advanced prostate cancer will be conducted through the Prostate Cancer Clinical Trials Consortium (PCCTC). Tesetaxel, an oral taxane which is in clinical development, will be evaluated for its use as both first- and second-line chemotherapy. […]